Pulmonary vascular disease & thromboembolism

Heart Rate Control with Landiolol Hydrochloride in Infants with Ventricular Dysfunction and Pulmonary Hypertension

ESC Heart FailPublished Retrospective cohort study

Authors' conclusion

The use of landiolol hydrochloride for HR control of non-arrhythmic tachycardia in critically ill infants is well tolerated. Reduction of HR can be guided quickly and landiolol treatment is associated with an improvement of ventricular dysfunction and PH.

Study context

Population
Term and preterm infants with ventricular dysfunction and/or pulmonary hypertension with preexisting tachycardia treated with landiolol, University Children's Hospital Bonn, 2018–2020
Participants
62 participants
Exposure
Landiolol in infants born <35 vs >35 weeks gestational age (GA)
  • Group An = 29
  • Group Bn = 33
Outcome
Percentage of patients achieving HR normalization
Follow-up
First 24 h of landiolol treatment
Methodological detailssingle-centre, medical chart review
  • Single-centre
  • Medical chart review

Main finding

As reported in the abstract

HR normalization · first 24 h

Primary endpoint achieved (overall)

57 patients

91.9%

Observational data: associations, not effects.

Further findings

Time to target HR

Median time to target HR (overall)
1.8 (0.3-24) h

Landiolol dosing

μk/kg/min

Median starting dose
8.8 (3.9-25.3)
Median dosing during first 24 h
9.9 (2.8-35.4)
Median dose at target HR
10 (2.4-44.4)

RV dysfunction · 24 h after onset of landiolol

Improved significantly in Group A
P = 0.001
Improved significantly in Group B
P = 0.045

LV and biventricular dysfunction (Group B) · 24 h after onset of landiolol

LV dysfunction improved significantly in Group B
P = 0.004
Biventricular dysfunction improved significantly in Group B
P = 0.006

Pulmonary hypertension (PH) severity (Group A) · 24 h

PH severity improved significantly in Group A
P < 0.001

Safety

Severe drug-related adverse events · during landiolol treatment

No severe drug-related adverse event

Original publication

Heart Rate Control with Landiolol Hydrochloride in Infants with Ventricular Dysfunction and Pulmonary Hypertension. ESC Heart Fail. Published 18 October 2022. doi:10.1002/ehf2.14202

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.